Home Cart Sign in  
Chemical Structure| 189188-57-6 Chemical Structure| 189188-57-6

Structure of Tegaserod maleate
CAS No.: 189188-57-6

Chemical Structure| 189188-57-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tegaserod Maleate is a potent full agonist at 5-HT4 receptors with an EC50 value of 7 nM, used to treat irritable bowel syndrome associated with constipation and chronic constipation.

Synonyms: HTF-919; SDZ-HTF-919; Zelnorm

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tegaserod maleate

CAS No. :189188-57-6
Formula : C20H27N5O5
M.W : 417.46
SMILES Code : COC1=CC2=C(NC=C2/C=N/NC(NCCCCC)=N)C=C1.O=C(O)/C=C\C(O)=O
Synonyms :
HTF-919; SDZ-HTF-919; Zelnorm
MDL No. :MFCD04116201

Safety of Tegaserod maleate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Tegaserod maleate

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK-293 cells 10 pM–100 μM 15 minutes To evaluate the agonist activity of Tegaserod at human recombinant 5-HT4(c) receptors, results showed high potency (pEC50=8.6±0.2) and full agonist activity. PMC1575425
KYSE150 cells 0, 3.125, 6.25, 12.5, 25, 50 µM 24 and 48 hours To evaluate the cytotoxic effect of Tegaserod Maleate on KYSE150 cells, showing an IC50 value of 6.867 µM (48 hours). PMC8372369
Schwann cells 100 nM 24 hours Evaluate the effect of Tegaserod on neurite extension, results showed that Tegaserod significantly promoted neurite extension at 100 nM concentration PMC4618794
Motoneurons 100 nM 24 hours Evaluate the effect of Tegaserod on neurite extension, results showed that Tegaserod significantly promoted neurite extension at 100 nM concentration PMC4618794
Dorsal root ganglion (DRG) neurons 100 nM 24 hours Evaluate the effect of Tegaserod on neurite extension, results showed that Tegaserod significantly promoted neurite extension at 100 nM concentration PMC4618794
Cerebellar granule neurons (cGNs) 100 nM 24 hours Evaluate the effect of Tegaserod on neurite extension, results showed that Tegaserod significantly promoted neurite extension at 100 nM concentration PMC4618794
Rat hippocampal neurons 0.5 nM to 1 µM 24 hours To evaluate the neuroprotective effects of Tegaserod on neuronal survival and neurite network. Results showed that Tegaserod at low concentrations (5 and 50 nM) could protect neurons from death and exerted protective effects on the neurite network. PMC8540544
Caco-2 cells 10 μM 30 minutes To evaluate the protective effect of 5-HT4 receptor activation against oxidative stress-induced apoptosis, results showed that tegaserod significantly improved the survival rate of Caco-2 cells PMC5159265
CHO-K1 cells 10 pM–30 μM 30 minutes To assess the binding affinity of Tegaserod at human recombinant 5-HT2B receptors, results showed high affinity (pKi=8.4±0.1). PMC1575425
22RV-1 0, 2.5, 5, 7.5, 10, 12.5, 15 μM 48 hours Detect cell viability, results showed that TM significantly inhibited the growth of PCa cells PMC11780919
PC-3 0, 2.5, 5, 7.5, 10, 12.5, 15 μM 48 hours Detect cell viability, results showed that TM significantly inhibited the growth of PCa cells PMC11780919
DU145 0, 2.5, 5, 7.5, 10, 12.5, 15 μM 48 hours Detect cell viability, results showed that TM significantly inhibited the growth of PCa cells PMC11780919
Caco-2 cells 1 μM 48 hours To evaluate the effect of 5-HT4 receptor activation on epithelial cell migration, results showed that tegaserod significantly increased the migration rate of Caco-2 cells PMC5159265
Human visceral afferent neurons 30 μM 5 minutes Tegaserod significantly reduced human nociceptor mechanosensitivity (−20.8±6.9%, n=6, p<0.05), suggesting that its efficacy for the treatment of pain in IBS may be mediated through the reduction of visceral nociceptor mechanosensitivity. PMC5754853
Rabbit isolated gastric antrum circular muscle 0.1–10 μM 60 min Tegaserod concentration-dependently potentiated EFS-evoked cholinergically-mediated contractions (maximal facilitation: 202±63%) with prolonged response duration (t1/2~28 min). This effect was mediated via 5-HT4 receptor activation and antagonized by SB-204070A. PMC2189716

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 J mice Syngeneic intravenous and subcutaneous melanoma xenografts Intraperitoneal injection 5 mg/kg Once daily for 5 days Evaluate the efficacy of TM against melanoma tumor growth, metastasis, and survival PMC7035645
C57BL/6J mice Femoral nerve injury model Local administration 250 nM or 2500 nM Single administration, lasting 15 weeks Evaluate the effect of Tegaserod on functional recovery after femoral nerve injury, results showed that 250 nM Tegaserod significantly promoted functional recovery and increased muscle mass PMC4618794
Sprague-Dawley rats Anesthetized rats Intravenous or intraduodenal 0.3–1.0 mg/kg Single dose or 7-day oral treatment To evaluate the effects of tegaserod on mesenteric and colonic blood flow in rats, showing no inhibitory effect on mesenteric and colonic blood flow. PMC2782331
Sprague-Dawley rats Visceral hypersensitivity model Intraperitoneal injection 0.1, 0.3 and 1.0 mg/kg Single dose, rectal distension performed 10 minutes after injection Tegaserod significantly inhibited the response to rectal distention in rats with visceral hypersensitivity and dose-dependently attenuated c-Fos expression in limbic system, especially in anterior cingulate cortex. PMC4572113
Sprague-Dawley rats Colonic inflammation model Intra-gastric administration 2 mg/kg and 1 mg/kg Once daily for 7 consecutive days To investigate the effects of tegaserod on Fos, substance P (SP), and calcitonin gene-related peptide (CGRP) expression in the lumbarsacral spinal cord induced by colonic inflammation. Results showed that tegaserod (2 mg/kg·d) significantly reduced Fos-labeled neurons and SP density in the dorsal horn of the spinal cord, but had no significant effect on CGRP content. PMC4572280

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.40mL

0.48mL

0.24mL

11.98mL

2.40mL

1.20mL

23.95mL

4.79mL

2.40mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories